Posts by Helene Kuhn
Differentiating sepsis and systemic inflammatory response syndrome using biomarkers
An interview with Dr. Richard Brandon, Chief Scientific Officer, Immunexpress, conducted by April Cashin-Garbutt, MA (Cantab).
Read MoreBrief-Biocartis & Immunexpress Partnership For A Sepsis Host Immune Response Test
Immunexpress and Biocartis enter an agreement to develop and commercialize SeptiCyte™ technology for use on sample-to-result Idylla™ platform.
Read MoreBiocartis, Immunexpress Partner to Develop Sepsis Test
Biocartis and Immunexpress partner to develop a fully automated sepsis test, allowing for fast near-patient testing, resulting in potentially life-saving clinical information.
Read MoreBiocartis, Immunexpress Partner to Develop Sepsis Test
Biocartis & Immunexpress sign partnership for a sepsis host immune response test on the Idylla™ platform.
Read MoreBiocartis Partnership May Enable Immunexpress to Move Sepsis Test to Point of Care
Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company and Immunexpress have entered into a partnership agreement aimed at the development and commercialization of Immunexpress’ SeptiCypte™ test for use on Biocartis’ sample-to-result Idylla™ platform.
Read MoreProduct Briefs – SeptiCyte LAB
Immunexpress, Inc. published in the American Journal of Respiratory and Clinical Care Medicine the design and results of clinical trials validating SeptiCyte™ LAB in the discrimination of sepsis from non-infectious systemic inflammatory response syndrome (SIRS) in the Intensive Care Unit (ICU) of hospitals.
Read MoreAppointments and advancements – Rolland Carlson, Tanja Dowe, Katleen Verleysen
Immunexpress strengthens Board of Directors with key appointments.
Read MoreAppointments and advancements – Fayyaz Memon
Immunexpress continues executive team expansion with addition of Fayyaz Memon as VP of Regulatory Affairs & Quality.
Read MoreInternational Sepsis Forum 2016
International Sepsis Forum 2016 December 6-8, 2016 Paris, France. Marc Bonten, founder of the MARS sepsis consortium presented SeptiCyte™ LAB data and by Thierry Calandra, author of the international Surviving Sepsis campaign also discussed the utility of SeptiCyte™ in ICU management. Independent investigators from the Utrecht Medical Centre presented data from two investigator lead trials…
Read MoreFDA public hearing: Microbiology Medical Devices Panel for Sepsis
FDA public hearing: Microbiology Medical Devices Panel for Sepsis November 10, 2016 Washington, DC. This was an open hearing on how recent regulatory changes affect the application of host response sepsis diagnostics for the clinical management of Antibiotics. Attended by the FDA Molecular Diagnostics Advisory Board IXP Staff in Attendance: Leo McHugh, Roy Davis
Read More